Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.
The cancer therapy, marketed by Johnson & Johnson, demonstrated robust performance across major markets. United States sales reached $2.208 billion, while international markets generated $1.756 billion in revenue.
Genmab earns royalties on worldwide DARZALEX sales through its licensing agreement with Johnson & Johnson. The therapy treats multiple myeloma and remains a key revenue driver for the company. DARZALEX is available in both intravenous and subcutaneous formulations, providing treatment options for patients with this serious blood cancer.
GMAB is currently trading at $29.10, up $0.90 or 3.21 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.